睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由空军军医大学西京医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方空军军医大学西京医院Xijing Hospital西安医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06914440,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:仅女性

    登记记录的入选字段

  2. Histologically confirmed non-metastatic (M0) breast cancer, meeting all of the following:

    入选标准第 3 条

    Histologically or pathologically confirmed invasive carcinoma, with all of the following:

    入选标准第 4 条

    Grade 2 or 3 (confirmed by central laboratory);

    入选标准第 5 条

  3. Thyroid function:TSH ≤1×ULN; if abnormal, normal T3/T4 levels required for eligibility.

    入选标准第 16 条

  4. No prior antitumor therapy within 1 month before enrollment.

    入选标准第 10 条

    Prior systemic targeted therapy or immunostimulants (e.g., interferon, IL-2) within 4 weeks before treatment;

    排除标准第 18 条

    Clinical Trial Participation: participation in another drug trial within 4 weeks prior to enrollment, or within 5 half-lives of the last investigational drug dose.

    排除标准第 20 条

  5. ECOG PS status of 0-1.

    入选标准第 2 条

  6. Complete blood count (no transfusion or hematopoietic growth factors within 7 days): ANC ≥1.5×10⁹/L; ALC ≥0.5×10⁹/L; Platelets ≥100×10⁹/L; Hemoglobin ≥90 g/L; WBC ≥3.0×10⁹/L and ≤15×10⁹/L;

    入选标准第 12 条

    Blood biochemistry (no transfusion/albumin within 7 days): ALT/AST ≤2.5×ULN; ALP ≤2.5×ULN;BUN/Cr ≤1.5×ULN; Cr≥60 mL/min (Cockcroft-Gault formula);

    入选标准第 13 条

    Coagulation: PT/APTT ≤1.5×ULN; INR ≤1.5×ULN (if no anticoagulant therapy);

    入选标准第 14 条

    Coagulation abnormalities (INR >1.5×ULN or APTT >1.5×ULN), or requiring long-term anticoagulation (warfarin/heparin) or antiplatelet therapy (aspirin≥300 mg/day or clopidogrel ≥75 mg/day).

    排除标准第 16 条

  7. Malignancy History: other malignancies diagnosed within 5 years prior to enrollment (except adequately treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ);

    排除标准第 9 条

  8. Have a negative serum pregnancy test within 7 days before treatment;

    入选标准第 18 条

    Use highly effective contraception during the study and for 180 days after the last dose.

    入选标准第 19 条

    Pregnancy/Lactation: pregnant, breastfeeding, or planning pregnancy during the study.

    排除标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06914440,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Female patients aged ≥18 and ≤75 years at the time of signing informed consent.
  2. ECOG PS status of 0-1.
  3. Histologically confirmed non-metastatic (M0) breast cancer, meeting all of the following:
  4. Histologically or pathologically confirmed invasive carcinoma, with all of the following:
  5. Grade 2 or 3 (confirmed by central laboratory);
  6. ER-positive (>1% staining) and/or PR-positive (>1% staining) by IHC;
  7. HER2-negative (IHC 0/1+ or HER2/neu FISH ratio ≤1.8);
  8. Ki-67 ≥15%.
  9. Patient deemed eligible for radiotherapy after MDT evaluation.
  10. No prior antitumor therapy within 1 month before enrollment.
  11. Organ Function Requirements (within 7 days prior to enrollment):
  12. Complete blood count (no transfusion or hematopoietic growth factors within 7 days): ANC ≥1.5×10⁹/L; ALC ≥0.5×10⁹/L; Platelets ≥100×10⁹/L; Hemoglobin ≥90 g/L; WBC ≥3.0×10⁹/L and ≤15×10⁹/L;
  13. Blood biochemistry (no transfusion/albumin within 7 days): ALT/AST ≤2.5×ULN; ALP ≤2.5×ULN;BUN/Cr ≤1.5×ULN; Cr≥60 mL/min (Cockcroft-Gault formula);
  14. Coagulation: PT/APTT ≤1.5×ULN; INR ≤1.5×ULN (if no anticoagulant therapy);
  15. Urinalysis: Urine protein <2+; if ≥2+, 24-hour urine protein must be ≤1g;
  16. Thyroid function:TSH ≤1×ULN; if abnormal, normal T3/T4 levels required for eligibility.
  17. Women of childbearing potential must:
  18. Have a negative serum pregnancy test within 7 days before treatment;
  19. Use highly effective contraception during the study and for 180 days after the last dose.
  20. Voluntarily sign informed consent, demonstrate good compliance, and commit to follow-up.

排除标准:Exclusion Criteria:

  1. Inflammatory Breast Cancer.
  2. Comorbidities/Medical History:
  3. Autoimmune disease: patients with any known or suspected autoimmune disease, except: hypothyroidism due to autoimmune thyroiditis managed with hormone replacement therapy only, stable type-1 diabetes with well-controlled blood glucose.
  4. Cardiovascular Diseases: poorly controlled hypertension despite medication (SBP >140 mmHg or DBP>90 mmHg). And with the history (within 6 months prior to enrollment) of myocardial infarction, severe/unstable angina, NYHA Class ≥2 heart failure, clinically significant arrhythmias as well as symptomatic congestive heart failure.
  5. Interstitial lung disease, non-infectious pneumonitis, or other uncontrolled systemic diseases (e.g., diabetes, pulmonary fibrosis, acute pneumonia);
  6. Vaccination: receipt of live attenuated vaccines within 28 days prior to enrollment or planned during the study;
  7. Infections: HIV/AIDS, active hepatitis(HBV-DNA ≥500 IU/mL; HCV-RNA above detection limit), or co-infection with HBV and HCV, severe infections within 4 weeks prior to enrollment (e.g., bacteremia, severe pneumonia requiring hospitalization), active infection requiring systemic antibiotics (CTCAE≥Grade 2) within 2 weeks prior to treatment, active tuberculosis within 1 year prior to enrollment;
  8. Unexplained fever >38.5°C during screening (unless deemed tumor-related by the investigator);
  9. Malignancy History: other malignancies diagnosed within 5 years prior to enrollment (except adequately treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ);
  10. Surgery:Major surgery within 28 days prior to enrollment (diagnostic biopsies or PICC line placement are allowed);
  11. Transplant: Prior or planned allogeneic bone marrow or solid organ transplant;
  12. Neurological: peripheral neuropathy ≥Grade 2;
  13. Gastrointestinal: clinically significant bowel obstruction;
  14. Thrombotic Events: arterial/venous thrombosis within 6 months prior to enrollment (e.g., stroke, transient ischemic attack, DVT, pulmonary embolism);
  15. Bleeding Risk: hemoptysis (≥2.5 mL/day) within 2 months prior to enrollment, clinically significant bleeding within 3 months prior to enrollment (e.g. gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood≥++), and the known bleeding/thrombotic disorders (e.g., hemophilia, coagulopathy, thrombocytopenia, hypersplenism);
  16. Coagulation abnormalities (INR >1.5×ULN or APTT >1.5×ULN), or requiring long-term anticoagulation (warfarin/heparin) or antiplatelet therapy (aspirin≥300 mg/day or clopidogrel ≥75 mg/day).
  17. Treatment-Related Exclusions:
  18. Prior systemic targeted therapy or immunostimulants (e.g., interferon, IL-2) within 4 weeks before treatment;
  19. Known allergy to the investigational drug (recombinant humanized anti-PD-1 mAb) or its excipients.
  20. Clinical Trial Participation: participation in another drug trial within 4 weeks prior to enrollment, or within 5 half-lives of the last investigational drug dose.
  21. Substance Abuse: history of drug/alcohol abuse or dependency.
  22. Pregnancy/Lactation: pregnant, breastfeeding, or planning pregnancy during the study.
  23. Investigator' s Discretion: other conditions that may compromise subject safety or study integrity (e.g., severe lab abnormalities, social factors).

引自 ClinicalTrials.gov, NCT06914440, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06914440,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06914440